References
- Ben-Menachem E.:Medical management of refractory epilepsy - Practical treatment with novel antiepileptic drugs. Epilepsia, 2014, 55, Suppl 1: 3–8.10.1111/epi.1249424400690
- Callaghan B.C., Anand K., Hesdorffer D., Hauser W.A., French J. A.:Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol., 2007, 62: 382–389.10.1002/ana.2116617880009
- Chung S.:Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert. Opin. Pharmacother., 2010, 11: 1559–1602.10.1517/14656566.2010.48863920482307
- Chung S., Ben-Menachem E., Sperling M.R., Rosenfeld W., Fountain N.B., Benbadis S. et al.:Examining the clinical utility of lacosamide: Pooled analyses of three phase II/III clinical trials. CNS Drugs, 2010a, 24: 1041–1054.10.2165/11586830-000000000-0000021090838
- Chung S., Sperling M.R., Biton V., Krauss G., Hebert D., Rudd G.D. et al.:Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia, 2010b, 51: 958–967.10.1111/j.1528-1167.2009.02496.x20132285
- Contin M., Albani F., Riva R., Candela C., Mohamed S., Baruzzi A.:Lacosamide therapeutic monitoring in patients with epilepsy: Effect of concomitant antiepileptic drugs. Ther. Drug Monit., 2013, 35: 849–852.10.1097/FTD.0b013e318290eacc23942540
- Fröscher W.:Drug resistant epilepsy. Epileptologia, 2012, 20: 17–23.
- Fröscher W., Auner M., Kirschbaum J.:Behandlungsergebnisse bei pharmakoresistent erscheinenden Patienten (Therapeutic results in apparent drug-refractory epileptics). Akt. Neurol., 1989, 16: 1–8.10.1055/s-2007-1020571
- Fröscher W., Rösche J.:Kombinationstherapie bei Epilepsie (Combination therapy for epilepsy). Fortschr. Neurol. Psychiat., 2013, 80: 9–20.10.1055/s-0031-129936122450761
- Greenaway C., Ratnaraj N., Sander J.W., Patsalos P.N.:A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy. Ther. Drug Monit., 2010, 32: 448–452.10.1097/FTD.0b013e3181dcc5fb20386357
- Hoy S.M.:Lacosamide: A review of its use as adjunctive therapy in the management of partial-onset seizures. CNS Drugs, 2013, 27: 1125–1142.10.1007/s40263-013-0123-524203890
- Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Hauser W.A., Mathern G. et al.:Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia, 2010, 51: 1069–1077.10.1111/j.1528-1167.2009.02397.x19889013
- Kwan P., Schachter St.C., Brodie M.J.:Drug resistant epilepsy. N. Engl. J. Med., 2011, 365: 919–926.10.1056/NEJMra100441821899452
- Luciano A.L., Shorvon S.D.:Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann. Neurol., 2007, 62: 375–38110.1002/ana.2106417253624
- Mula M.,Godi L., Onorato S., Savoini G.:Successful treatment of super-refractory status epilepticus with intravenous la-cosamide. Epileptologia, 2012, 20: 81–85.
- Munger Clary H., Choi H.:Prognosis of intractable epilepsy: Is long-term seizure freedom possible with medical management? Clin. Neurol. Neurosci. Rep., 2011, 11: 409–417.10.1007/s11910-011-0199-621461679
- Neligan A., Bell G.S., Sander J.W., Shorvon S.D.:How refractory is refractory epilepsy? Patterns of relapse and remission in people with refractory epilepsy. Epilepsy Res., 2011, 96: 225–230.10.1016/j.eplepsyres.2011.06.00421724372
- Patsalos P.N.:Drug interactions with the newer antiepileptic drugs (AEDs) – Part 1. Pharmacokinetic and pharmacodynamic interactions between AEDs. Clin. Pharmacokinet., 2013, 52: 927–966.10.1007/s40262-013-0087-023784470
- Pedersen B., Rasmussen J.B.:Lacosamide treatment – added value of plasma levels? Epilepsia, 2013, 54, Suppl 3: 171.
- Sattler A., Schaefer M., May T.W., Rambeck B., Brandt C.:Fluctuation of lacosamide serum concentrations during the day and occurrence of drug reactions – first clinical experience. Epilepsy Res., 2011, 95: 207–212.10.1016/j.eplepsyres.2011.03.01921543186
- Schiller Y., Najjar Y.:Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology, 2008, 70: 54–65.10.1212/01.wnl.0000286959.22040.6e18166707
- Vimpat® product information (Fachinformation). UCB Pharma GmbH, Monheim, Germany. 31.7.2013.
- Wittstock M., Benecke R., Rösche J.:Transient third-degree atrioventricular block following rapid lacosamide titration in a patient with nonconvulsive status epilepticus. Epileptologia, 2011, 19: 165–169.
- Zaccara G., Perucca P., Loiacono G., Giovanelli F., Verrotti A.:The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia, 2013, 54: 66–74.10.1111/j.1528-1167.2012.03589.x22779776